Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 17-18, 2022. The links can also be found at www.sidoticonference.com/events.
| |||
Presentation Agenda | |||
Wednesday, August 17th, 2022 (Day 1) | |||
8:30-9:00 | |||
9:15-9:45 | |||
10:00-10:30 | ***** | ||
10:45-11:15 | |||
11:30-12:00 | |||
12:15-12:45 | |||
1:00-1:30 | |||
1:45-2:15 | |||
2:30-3:00 | ***** | ||
3:15-3:45 | ***** | ||
4:00-4:30 | ***** | ||
1x1s Only | Gulf Island Fabrication (GIFI) | Kelly Services (KELYA) | |
| |||
Thursday, August 18th, 2022 (Day 2) | |||
9:15-9:45 | |||
10:00-10:30 | |||
10:45-11:15 | |||
11:30-12:00 | |||
12:15-12:45 | |||
1:00-1:30 | |||
1x1s Only | American Woodmark (AMWD) | Paysign, Inc. (PAYS | Wireless Telecom Group (WTT) |
About Sidoti
For over two decades, Sidoti has been a premier provider of independent securities research focused specifically on Small Cap and Micro-Cap companies and the institutions that invest their securities, with most of our coverage in the $50 million to $3 billion market cap range. Our approach affords companies and institutional clients a combination of high-quality research, a Small Cap and Micro-Cap focused nationwide sales effort, and broad access to corporate management teams. We serve 500+ institutional clients in the U.S. and Canada, including many leading institutional managers. Sidoti promotes meaningful interaction between issuers and investors in the Small Cap and Micro-Cap space through a series of investor conferences (www.sidoti.com/events) we host each year.
CONTACT
Sidoti Events Team
212-453-7031
conference@sidoti.com
| Last Trade: | US$1.11 |
| Daily Change: | -0.04 -3.48 |
| Daily Volume: | 645 |
| Market Cap: | US$45.600M |
February 14, 2025 December 23, 2024 November 13, 2024 September 25, 2024 July 22, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
